Login to Your Account



Immunicum Closes Funds for Dendritic Cell Vaccine Trial

By Cormac Sheridan
BioWorld International Correspondent

Wednesday, November 30, 2011
Immunicum AB is finalizing the first closing of an SEK25 million (US$3.6 million) financing round to take forward a series of therapeutic vaccine technologies for treating cancer.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription